Intrauterine growth restriction (IUGR), or fetal growth restriction (FGR), is a serious complication of human pregnancy. IUGR is conceptualized as a fetus failing to achieve its genetically pre-determined growth potential, and contrasts with the diagnosis of SGA, which reflects newborn birth weights below the 10th percentile for an uncomplicated obstetric population. IUGR affects 3-10% of first time births, and contributes to one-third of all antepartum deaths, a tenfold increase in perinatal mortality and severe neurodevelopmental disabilities. IUGR may portend health complications in adult life, increasing the risk of hypertension, cardiovascular disease and diabetes. These are chronic conditions attributed to “fetal programming”.Today we lack greater specificity in diagnosis of IUGR, which is essential to identify pregnancies at risk and those that would benefit from the development of in utero therapies. A new estimated placental volume (EPV) method was performed in a study at Oslo University Hospital. It was hypothesized that estimated placental volume measurement based on 2-dimensional ultrasound at gestational weeks 17-19 could be correlated to clinical pregnancy outcome parameters, such as preeclampsia and/or IUGR.The study was performed on pregnant women attending routine ultrasound screening by midwives. Placentas were imaged and measurements recorded. After delivery all medical charts were retrospectively reviewed and EPV calculated. Women with the smallest placentas were at higher risk of pregnancy complicated by preeclampsia and/or IUGR. Identifying a small EPV before mid-pregnancy could assist in selecting at-risk pregnancies for closer surveillance.